Nexus BioQuest ads

📍 Nexus BioQuest is heading to PEGS Europe 2026! We're excited to announce that our Business Development Executive, Dr Karina Di Gregoli, PhD, and Principal Scientist, Dr Silvia Rosini, will be attending the 18th Annual PEGS Europe Protein & Antibody Engineering Summit in Lisbon from 16th-19th November. As one of the leading events in biologics and protein engineering, PEGS Europe brings together scientists and industry experts advancing the next generation of antibody therapeutics, AI-driven protein engineering, T cell engagers, autoimmune disease therapies, immuno-engineering, and much more. We're also proud to be presenting two scientific posters that showcase Nexus BioQuest's expertise in immunology and biologics research: 🔬 Bridging the Translational Gap: In vitro platforms for evaluating mechanisms of therapeutic depletion Demonstrating our expertise in human-relevant depletion modelling, we combine advanced imaging, proteomics, and human in vitro models to deliver data-driven insights that accelerate next-generation therapeutics. 🔬 Beyond Binding: Human Immune Cell Assays for Assessing Antibody Fc Function Exploring how we use translational ex vivo models to demonstrate how functional Fc profiling differentiates candidates, identifies potential immunotoxicity risks, and informs pre-IND decision-making, using translational ex vivo models. Whether you're developing next-generation biologics, investigating immune mechanisms, or looking for translational preclinical models to de-risk your pipeline, we'd love to connect. 📅 Attending PEGS Europe? Stop by and meet Karina and Silvia to discuss your research challenges and discover how Nexus BioQuest can help accelerate your programme. 📩 Prefer to schedule a meeting in advance? Contact us at [email protected] See you in Lisbon! #PEGSEurope #PEGS2026 #Biologics #ProteinEngineering #AntibodyDiscovery #Immunology #Immunotherapy #DrugDevelopment #TranslationalResearch #CRO

🔬 Targeting T Follicular Helper Cells to Prevent Pathogenic B Cell Differentiation Targeting T follicular helper (Tfh) cells is a promising strategy to stop the growth, differentiation and survival of autoreactive B cells in autoimmune disease. Using our secondary lymphoid organ (SLO) model, we demonstrated that rosnilimab efficiently depletes PD-1⁺ CD4⁺ T cell populations, primarily GC Tfh cells, but also Tconv PD-1⁺ cells, in the presence of exogenous NK cells. This depletion was accompanied by concurrent reductions in downstream plasmablast frequencies and antibody production. Why is this important? Tfh cells reside within the germinal centres of SLOs, where they provide essential signals that drive B cell maturation and differentiation to plasma cells. By depleting or blocking Tfh cells, it may be possible to interrupt these signals, limiting the generation of autoreactive B cell clones and plasma cells. At Nexus BioQuest, we offer assays that test therapeutic efficacy of targeting the drivers (Tfh) or effector (B cells) that underly many autoimmune diseases, such as SLE, RA, Sjögren's disease, ANCA-associated vasculitis (AAV). To learn more about our ADCC-mediated B cell depletion assays and immune cell functional models, contact us at [email protected] or visit www.nexusbioquest.com. #AutoimmuneDisease #Immunology #DrugDiscovery #TranslationalResearch #NexusBioQuest #CRO #PreclinicalResearch

We're heading to SITC 2026! It's that time of year again... the Nexus BioQuest team is excited to be attending the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026, in Arizona, USA. Join our team at Booth 413, where our Head of European BD Dr Anna Willox, Business Development Executive Dr Boris Simonetti, PhD, and Principal Scientist Dr Christopher Rice will be on hand to connect, collaborate, and discuss the latest advances in immuno-oncology. SITC brings together leading researchers, clinicians, regulatory bodies, and industry experts from across the globe, all working towards a common goal: advancing cancer immunotherapy and improving outcomes for patients. We're looking forward to showcasing how our translational 3D co-culture tumour models and advanced proteomics platform can help accelerate early-stage immuno-oncology discovery, from exploring disease biology and tumour-immune interactions to identifying drug-specific immune responses. If you're attending SITC, we'd love to meet you. Stop by Booth 413 to learn how Nexus BioQuest can support your research, or contact us at [email protected] to arrange a meeting in advance. See you in Arizona! 👋 #SITC2026 #ImmunoOncology #DrugDiscovery #Proteomics #TranslationalResearch #Immunology #CRO

Looking to identify protein biomarker changes in neurodegenerative disease in response to therapeutic treatment? At Nexus BioQuest, we're proud to be a certified provider of Olink™ Technology, a leading platform for high-throughput, ultra-sensitive protein biomarker discovery and validation. Using our Omycx™ platform, we help our clients uncover protein biomarkers associated with mechanism of action and therapeutic response, providing valuable insights to support confident translational decision-making. Our dedicated neurodegeneration panel includes proteins linked to four key biological processes: 🧠 Neurodegeneration 🧠 Synaptic function 🧠 Protein clearance 🧠 Vascular function By comparing treated and untreated conditions, we generate comprehensive proteomic signatures and benchmark drug responses against clinical reference compounds, helping to bridge the gap between preclinical findings and clinical relevance. If you're advancing therapies for neurodegenerative diseases and need robust biomarker data to inform development, we'd love to discuss how we can support your research. 📧 [email protected] #Neurodegeneration #Proteomics #Biomarkers #DrugDiscovery #TranslationalResearch #TherapeuticDevelopment #ProteinBiomarkers #Immunology #CRO #Omycx

For this month's 'Feedback Friday' we’re proud to showcase this wonderful feedback from Olfera: ‘Working with Nexus BioQuest has been a great experience. The team is genuinely science-driven, and everyone truly understands the biology behind the work, not just the logistics. The quality of research has been consistently high, and we've really appreciated collaborating with the Nexus BioQuest team!’ Thank you Parnian Lak, it was a pleasure collaborating with you.

How predictive are your tumour models? To better predict clinical outcomes, models that recapitulate the complexity of the tumour microenvironment are needed. At Nexus BioQuest, our 3D co-culture tumour models bridge the gap between conventional cell culture and in vivo studies, delivering greater biological and translational relevance, while generating more predictive preclinical data. Using SK-OV-3 ovarian cancer cells and normal human dermal fibroblasts, we've demonstrated how stromal cells can significantly influence therapeutic efficacy, highlighting their critical role in treatment resistance. Combined with Opera Phenix® high-content imaging, these models provide powerful insights into tumour biology and therapeutic response. Our 3D co-culture models can help you: 🔬 Investigate tumour-immune interactions in a more physiologically relevant setting 💊 Evaluate immunotherapies and combination treatment strategies 📊 Assess gene expression changes associated with tumour invasion and progression 🧬 Explore stromal-driven resistance mechanisms A key advantage of these complex multicellular models is their flexibility. Models can be customised to incorporate different cell types and disease contexts, providing the biologically relevant environment needed to evaluate target engagement and therapeutic efficacy, crucial for increasingly complex, multi-target therapies. Ready to enhance the translational relevance of your immuno-oncology studies? Contact us or visit our website to learn more: 📩 [email protected] 🌐 www.nexusbioquest.com #ImmunoOncology #TumourMicroenvironment #3DCellCulture #DrugDiscovery #TranslationalResearch #Immunology #CRO